Clinical Research Papers:
Resected pancreatic ductal adenocarcinomas with recurrence limited in lung have a significantly better prognosis than those with other recurrence patterns
Metrics: PDF 683 views | HTML 728 views | ?
Tamna Wangjam1,9, Zhe Zhang1,6, Xian Chong Zhou1,6, Laxmi Lyer1,10 Farzana Faisal1, Kevin C. Soares1,2,6, Elliott Fishman4,6, Ralph H. Hruban1,3,6,8 Joseph M. Herman1,5,6, Daniel Laheru1,6,7, Matthew Weiss1,2,6, Min Li11 Ana De Jesus-Acosta1,6,7, Christopher L. Wolfgang1,2,3,6,8, Lei Zheng1,2,6,7,8
1Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
2Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA
3Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
4Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
5Department of Radiation Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
6The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
7The Skip Viragh Center for Pancreatic Cancer, Johns Hopkins University School of Medicine, Baltimore, MD, USA
8The Sol Goldman Pancreatic Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
9Division of Hematology and Oncology, University of Texas Health Science Center, San Antonio, TX, USA
10Division of Hematology and Oncology, University of Maryland School of Medicine, Baltimore, MD, USA
11University of Oklahoma Health Science Center, Oklahoma City, OK, USA
Lei Zheng, e-mail: firstname.lastname@example.org
Christopher L. Wolfgang, e-mail: email@example.com
Ana De Jesus-Acosta, e-mail: firstname.lastname@example.org
Keywords: pancreatic cancer, recurrent pattern, lung metastasis, prognosis
Received: June 26, 2015 Accepted: August 28, 2015 Published: September 10, 2015
The majority of patients with curative resection of pancreatic ductal adenocarcinoma recur within 5 years of resection. However, the prognosis associated with different patterns of recurrence has not been well studied. A retrospective review of patients who underwent curative surgical resection of pancreatic cancer was performed. Of the 209 patients, 174 patients developed recurrent disease. Of these 174, 28(16.1%) had recurrent disease limited to lung metastases, 20(11.5%) had recurrence in the lung plus one or more other sites excluding the liver, 73(42.0%) had liver metastasis alone or liver metastasis with any other site except lung, 28(16.1%) local recurrence only, and 25(14.3%) peritoneal recurrence alone or together with local recurrence. Patients with recurrence limited to lung had a 8.5 months(Mo) median survival from recurrence to death, which was significantly better than the survival associated with recurrence in the liver(5.1Mo), in the peritoneum(2.3Mo) or locally(5.1Mo) in multivariable analyses. Among all groups, the time from surgery to the diagnosis of recurrence in patients who recurred in only in the lung was also the longest. However, 75% of patients were found to have indeterminate lung nodules on their surveillance CT scans prior to the diagnosis of recurrence in lung. This delayed diagnosis of lung recurrence may have a negative impact on survival after recurrence. In conclusion, pancreatic cancer with lung recurrence has a significantly better prognosis than recurrence in other sites. Further studies are needed to investigate how different diagnostic and treatment modalities affect the survival of this unique subpopulation of pancreatic cancer patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.